Tag : GLUCOCORTICOIDS

CONFERENCE UPDATE

Attaining LLDAS and reducing GC use with anifrolumab in SLE patients: The TULIP-LTE study
In patients with systemic lupus erythematosus (SLE), Lupus Low Disease Activity State (LLDAS) attainment is associated with reduced flares, oral glucocorticoid (GC) dosing, damage accrual, and mortality. The post-hoc analysis of the 52-week phase 3 TULIP-1/-2 trials showed that patients with SLE who received anifrolumab were more likely to achieve LLDAS over the placebo group.
CONFERENCE UPDATE

New insights on the impact of tapering GCs or immunosuppressive therapy on damage accrual after achieving LLDAS and complete remission SLE
RESEARCH SPOTLIGHT

Exploring the association of systemic glucocorticoids and incident major adverse cardiovascular events in patients with rheumatoid arthritis based on real-world data
Despite their exceptional anti-inflammatory properties, the use of systemic glucocorticoids (GCs) for the treatment of rheumatoid arthritis (RA) remains controversial due to the potential side effects, particularly their role in elevating patients’ risk of cardiovascular (CV) events. A po

Dr. So, Ho

Assistant Professor, Division of Rheumatology, Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong

Ann Rheum Dis. 2023

So H, et al. Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study.